> Detailanzeige

Voss, Michael G.; Cuthbertson, David D.; Cleves, Mario M.; Xu, Ping; Evans-Molina, Carmella; Palmer, Jerry P.; Redondo, Maria J.; Steck, Andrea K.; Lundgren, Markus; Larsson, Helena; Moore, Wayne V.; Atkinson, Mark A.; Sosenko, Jay M.; Ismail, Heba M.; Greenbaum, Carla J.; Anderson, Mark; Atkinson, Mark A.; Bosi, Emanuele; Brusko, Todd M.; Buckner, Jane; Clements, Mark; Colman, Peter G.; Daniels, Mark; DiMeglio, Linda; [...]

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
  • Beteiligte: Voss, Michael G.; Cuthbertson, David D.; Cleves, Mario M.; Xu, Ping; Evans-Molina, Carmella; Palmer, Jerry P.; Redondo, Maria J.; Steck, Andrea K.; Lundgren, Markus; Larsson, Helena; Moore, Wayne V.; Atkinson, Mark A.; Sosenko, Jay M.; Ismail, Heba M.; Greenbaum, Carla J.; Anderson, Mark; Atkinson, Mark A.; Bosi, Emanuele; Brusko, Todd M.; Buckner, Jane; Clements, Mark; Colman, Peter G.; Daniels, Mark; DiMeglio, Linda; [...]
  • Erschienen: American Diabetes Association, 2021
  • Erschienen in: Diabetes Care
  • Sprache: Englisch
  • DOI: 10.2337/dc21-0226
  • ISSN: 0149-5992; 1935-5548
  • Schlagwörter: Advanced and Specialized Nursing ; Endocrinology, Diabetes and Metabolism ; Internal Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>We examined 2-h OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (mean ± SD age, 13.84 ± 9.53 years; BMI Z-score, 0.33 ± 1.07; 56.1% male) and 3,720 PTP participants (age, 16.01 ± 12.33 years; BMI Z-score, 0.66 ± 1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-score, HOMA-insulin resistance, and peak glucose/C-peptide levels, respectively) were performed.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose &amp;gt;30 min and time to peak C-peptide &amp;gt;60 min (P &amp;lt; 0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: χ2 = 25.76 vs. χ2 = 8.62; PTP: χ2 = 149.19 vs. χ2 = 79.98; all P &amp;lt; 0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>In two independent at-risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang